aromatase inhibition therapy

DRUG8 trials

Sponsors

National Cancer Institute (NCI), University of Nebraska, Azienda Ospedaliero-Universitaria di Modena, University of California, San Francisco, Virginia Commonwealth University

Conditions

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Breast AdenocarcinomaBreast CancerChemotherapeutic Agent ToxicityCognitive/Functional EffectsDuctal Breast Carcinoma in Situ

Phase 2

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

CompletedNCT00119262

National Cancer Institute (NCI)Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer +1

Start: 2005-10-31End: 2009-09-30Updated: 2014-05-15

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

CompletedNCT00499083

University of NebraskaBreast Cancer

Start: 2006-05-01End: 2010-01-28Updated: 2023-09-29

Phase 3

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

CompletedNCT00005970

National Cancer Institute (NCI)Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7 +4

Start: 2000-05-19End: 2010-01-27Updated: 2020-08-14

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

Azienda Ospedaliero-Universitaria di ModenaBreast Cancer

Start: 2007-12-31Target: 2500Updated: 2013-08-07

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

CompletedNCT02003209

National Cancer Institute (NCI)HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7 +5

Start: 2014-02-18End: 2025-06-30Updated: 2025-08-08

Unknown Phase

Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer

CompletedNCT00755313

University of California, San FranciscoBreast Cancer, Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects +4

Start: 2007-05-31End: 2014-06-06Updated: 2017-11-24

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

CompletedNCT01293032

Virginia Commonwealth UniversityDuctal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage IIA Breast Cancer +4

Start: 2011-04-30End: 2016-03-31Updated: 2016-07-12

Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer

RecruitingNCT06534125

Emory UniversityAnatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 +2

Start: 2024-12-12End: 2027-12-31Target: 150Updated: 2026-01-29

Related Papers

Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early <i>ERBB2</i>-Positive Breast Cancer

JAMA Oncology2025-02-139 citations

Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor–Positive, HER2-Positive Breast Cancer

Journal of the National Comprehensive Cancer Network2024-08-271 citations

Abstract PO4-25-04: MHC Class I and II Expression, Functional Tertiary Lymphoid Structure (TLS), and Outcomes in Early-Stage HER2-Positive (HER2+) Breast Cancer in NCCTG N9831 (Alliance)

Cancer Research2024-05-02

Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial.

Journal of Clinical Oncology2023-06-077 citations

Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.

Journal of Clinical Oncology2023-06-0112 citations

Abstract P2-11-05: Effects of Intrinsic Subtypes and 21-gene Assay on the Early and Late Recurrence Risks in Patients with Early Stage HER2+ Breast Cancer: An Analysis of the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) Trial

Cancer Research2023-03-01

Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial.

2023-02-048 citations

Abstract 5627: Functional tertiary lymphoid structure (TLS) and outcome in HER2-positive (HER2+) breast cancer in NCCTG N9831 (Alliance)

Cancer Research2022-06-15

Abstract 494: Role of age, BMI, and tumor subtype in racial/ethnic disparities in breast cancer survival: A pooled analysis of four Alliance adjuvant clinical trials

Cancer Research2022-06-15

Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.

Journal of Clinical Oncology2022-06-012 citations

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials.

2022-05-247 citations

Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715)

UNC Libraries2021-12-07

Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial.

2021-12-023 citations

Outcome and immune landscape of HER2-positive invasive lobular carcinoma in the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) trial.

Journal of Clinical Oncology2021-05-206 citations

Value of clinical treatment score post-5 years (CTS5) for late relapse risk assessment in patients with early-stage HER2+ breast cancer (BC) in the north central cancer treatment group (NCCTG) N9831 (Alliance) trial.

Journal of Clinical Oncology2020-05-20

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial.

2019-11-215 citations

Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31

Journal of Clinical Oncology2019-10-1769 citations

PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.

Journal of Clinical Oncology2019-05-208 citations

Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715)

The Oncologist2019-04-117 citations

Abstract PD3-02: Incidence of late relapse in HER2-positive (HER2+) breast cancer patients receiving adjuvant trastuzumab: Combined analysis of NCCTG (Alliance) N9831 and NSABP (NRG) B31

Cancer Research2019-02-156 citations

8 more papers not shown